1.99BMarket Cap
LossP/E TTM
Palvella Therapeutics Inc
Key Figures
147.610Open
149.540High
185.67KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.67%Turnover Ratio
150.190Prev. Close
138.740Low
19.34MTurnover
LossP/E Static
39.86P/B
0.00%Div Yield TTM
-28.73%ROA
151.18052wk High
1.16Volume Ratio
-17.43MNet Profit
11.09MShares
-4.1694EPS TTM
-0.14Beta
-34.25%ROE
20.20052wk Low
7.19%Amplitude
100.00%Gross Margin
1.99BMarket Cap
1.55Reward/Risk
4.55%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Palvella Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 229.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Palvella Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Palvella Therapeutics Inc Highlights
StrengthsRisks
Palvella Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Palvella Therapeutics Inc
PVLA
16
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Palvella Therapeutics Inc Info
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Ticker SymbolPVLA
CompanyPalvella Therapeutics Inc
CEOKaupinen (Wesley H)
Websitehttps://palvellatx.com/
Shareholders
FAQs
What is the current price of Palvella Therapeutics Inc (PVLA)?
The current price of Palvella Therapeutics Inc (PVLA) is 139.04.
What is the symbol of Palvella Therapeutics Inc?
The ticker symbol of Palvella Therapeutics Inc is PVLA.
What is the 52-week high of Palvella Therapeutics Inc?
The 52-week high of Palvella Therapeutics Inc is 151.18.
What is the 52-week low of Palvella Therapeutics Inc?
The 52-week low of Palvella Therapeutics Inc is 20.20.
What is the market capitalization of Palvella Therapeutics Inc?
The market capitalization of Palvella Therapeutics Inc is 1.54B.
Is Palvella Therapeutics Inc (PVLA) currently rated as Buy, Hold, or Sell?
According to analysts, Palvella Therapeutics Inc (PVLA) has an overall rating of Buy, with a price target of 229.00.
What is the Earnings Per Share (EPS TTM) of Palvella Therapeutics Inc (PVLA)?
The Earnings Per Share (EPS TTM) of Palvella Therapeutics Inc (PVLA) is -3.71.
